{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-152767","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.582117+00:00","generated_at":"2026-05-18T13:44:15.856656+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Inhibikase stockholders re-elect directors, ratify auditor, approve equity plan amendment at 2025 annual meeting","bullets":["Amit Munshi and David Canner re-elected as Class II directors with 56.8M and 57.7M votes for, respectively; 3.4M broker non-votes.","CohnReznick LLP ratified as independent auditor for FY2025: 61.1M votes for, 29k against, no broker non-votes.","Amendment to 2020 Equity Incentive Plan (evergreen provision) approved: 46.3M for, 11.4M against, 3.4M broker non-votes.","Annual meeting held June 27, 2025; no other matters voted on."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-152767","json":"https://secwatch.observer/filing/0001193125-25-152767.json","markdown":"https://secwatch.observer/filing/0001193125-25-152767.md","text":"https://secwatch.observer/filing/0001193125-25-152767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525152767/0001193125-25-152767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525152767/d109611d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:44:15.856656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}